The global short bowel syndrome market is expected to grow at a CAGR of almost 26% during the forecast period, 2017-2021.
Technavio has announced its latest market research report on the global short bowel syndrome (SBS) market, under its cardiovascular and metabolic disorders portfolio. This market analysis discusses the major drivers and key emerging trends and offers an analysis of key vendors like Emmaus Medical, Merck, and Shire.
According to Barath Palada, a lead analyst for cardiovascular and metabolic disorders research at Technavio, “Special drug designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted from paying the US FDA application fees. Such benefits help reduce the burden from vendors and encourage them to develop products for rare diseases.”
The R&D expenses are high for such novel molecules and hence, a special designation such as orphan drug status encourage the vendors to conduct such R&D, which otherwise would make the molecule economically unviable. For instance, Nutrinia is developing NTRA-9620, which is currently in Phase II for the treatment of pediatrics population, received orphan drug designation from the US FDA.
Click here to request a free sample of this report
Increased awareness of GI disorders
Drug manufacturers are distributing visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This helps increase the knowledge of the individuals about a particular GI disorder. Many NGOs also conduct camps to educate people and raise the awareness level. As SBS is also a portion of the bowel-rated diseases, the increasing awareness about the overall bowel health maintenance and remedial measures will benefit this niche market of SBS as well in terms of patient compliance and drug sales growth.
Focus on gene therapy
Gene therapy is a prominent option to treat intestinal disorders including SBS. As congenital SBS is largely due to a mutation in CLMP and FLNA gene, the ongoing research in gene therapy is trying to target the implantation of healthy genes to overcome this shortcoming. For instance, in January 2017, investigators at Children’s Hospital, Los Angeles, US, used a novel zebrafish model, a living vertebrate model organism used in translational medical research to perform extensive gene sequencing to map the genetic changes resulting from SBS
This research report includes an in-depth analysis and market shares and sizes of the sub-segments and geography. An analysis of the key companies, including their market shares, business overview, key financials, etc. is provided in this study. This market study also provides a detailed analysis of key drivers, challenges, and opportunities influencing this market.
A more detailed analysis is available in the Technavio report titled, ‘Global Short Bowel Syndrome Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global ENT Disorder Treatment Market 2017-2021
- Global Gastroparesis Drugs Market 2017-2021
- Global Neutropenia Treatment Market 2017-2021
To read more press releases – click here
